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becoine available and bring us a step closer to rapid results produced 
by real automatic equipment with an absolute minimum of hands- 
on time. An increasing number of publications confirin the excellent 
perforiiiance of this new instrument, not only for the identification 
of microorganisms, but particularly for susceptibility testing. The new 
concept comprises the determination of a enlarged range of MICs 
which are then andyzed by the antimicrobial expert system which 
has been designed and is continuously updated by a widely accepted 
international panel of experts. This approach takes us a step further 
from simple susceptibility testing using breakpoints and closer to the 
oriented detection of antimicrobial resistance mechanisms, useful 
recoiiiiiieiidatioiis and closer collaboration between clinicians and 
microbiologists. The impact on  the management of patients and on 
therapy has not yet been fully evaluated. In the view of worldwide 
cost constraints, restriction of hospital beds, shorter hospitalization 
time and shift t o  ambulatory medicine, it can be expected that more 
rapid and complete rewlts will be a cornerstone of cost-efficiency 
Sonic reorganizations of the microbiology laboratory will be neces- 
sary to optimize the possibilities offered by the VITEK 2. They adapt 
well to the increasing expectation of our technicians to work part- 
time, the extension of opening hours of laboratories and the 
streamlining of workflow in merging laboratories. 
)I Surveillance of antibiotic resistance: expert 
systems and surveillance networks 
K. Leclcrcq. Service de Alitmbiolo~qie, Cacw, Frame 
The  importance of antibiotic resistance surveillance is now recog- 
nized. It helps to control infections, to establish empirical antibiotic 
therapy protocols and to implement a policy of antibiotic usage. An 
effective surveillance system relies on  the combination of an inforin- 
ation system, automation and the ability to transfer data to other sites. 
A surveillance system should produce results leading to rapid and 
appropriate information and action. Whereas staiidard laboratory 
methods nieasure susceptibility or resistance to individual anti- 
microbials, most expert systems allow us to characterize in addition 
the resistance phenotypes of organisms and thus to infer resistance 
mechanisms. This in turn gives rire to better identification of 
epidemic strains or epidemic resistance mechanisms and therefore 
allows us to iiiiplement early infection control measures. Expert 
systems can also generate computer alerts, which play an important 
role in the early prevention of resistant organism transmission. The  
interest in expert systems is not limited to local surveillance and 
intervention but extends to national or global networks of antibiotic 
resistance. These networks should be supplied with homogeneous 
data resulting from standardized techniques. Combination of auto- 
mation and expert systems tends to satisfy this requirement, since it 
yield\ reproducible and repeatable results. Finally, the use of 
quantitative rather than qualitative data is an additional feature of 
certain systems. 
m] Molecular methods for diagnostic 
microbiology: current and future trends 
1). Persing. A f a y u  Clitrir Rorhesrcr, Rurhesfcr, hlN, L7s,4 
T h e  next generation of niolecular diagnostic tests for cancer, 
infectious diseases and genetic predisposition will depend on rnulti- 
locus genetic analysis, often involving analysis of  highly complex 
targets or mixtures of targets. Driven in part by the expansiou of the 
worldwide human genome projects, advances in DNA sequencing 
technology have resulted in systems that are easier to use and operate, 
at ever-decreasing cost. Genetic array technology is well suited to 
coiiiplex genetic analysis because of its 'ibility to carry out iiiultiplc 
types of reactions, including DNA sequencing and quantitative 
inRNA expression analysis. This presentation will provide some 
examples of new molecular diagnostic paradigms that involve IINA 
sequencing and array-based procedures, including the idcntificatioii 
and typing of microbes, evaluation of genetic predisposition to 
unusual outcomes of chronic infections, and the use of gciie 
expression patterns to classify disease states. 
Im Influence of new diagnostic methods on 
clinical practice 
K.G. Finch. The Ci ty  Hospiful, Dept. gfhlirrol~ioloy)~, Norriqj i ,m,  U K  
Currently there are major ~hortconi ing in thc laboratory definition 
of infection. Few cornniunity-managed infections are didgnosed with 
sufficient accuracy to impact on nianageiiient and, i n  turn, to provide 
a more complete picture of the true epidemiolog of infectious 
disease for the purposes of healthcare planning. Even among hos- 
pitalized patients, many infections reiiiain undocumented or, when 
defined, the managcment of only a minority ic influenced jigni- 
ficantly To impact on disease management more effectively, ideally 
new technologies should be available at the point of medical con- 
sult'ition, discriminate between infecting and colonizing pathogens, 
aid therapeutic management in a timely manner and, of courw, be 
afkrdable! Rapid culture-based diagnostics will partly address these 
issues. However, molecular-based diagnostics have the potential for 
greater impact, particularly if they are specimen based and iiot reliant 
on pure culture. The clinical features ofmany acute infections are not 
sutficiently discriminating to define etiology. Thus chip technology 
directed at syndromes wch as UTI, LIXTI. URTIE, STI), SSTI, 
nieiiingitis and jaundice' could have a major impact on disease 
definition and management. However, they will require new think- 
ing with regard to the definitions of disease and endpoint\ of 
response. The future will be very interexing. 
Respiratory infections: strategies for a 
resistance environment 
ml The resistance environment: a view from the 
Alexander Project 
P. Appelbauni. Hcrsliey A21cdiral Chcrltcr, Herslrey, PA, [ I 6 4  
Resimiice mechanisms have emerged against all classes of antibiotic\ 
so, in the absence of novel agents, it is important that the right 
antibiotics are uwd to obtain the optimal tredtiiicnt outcome, while 
ndniiiiizing the impact of resistance. High-quality surveillance pro- 
grams, such as the Alexander Project, are necessary to monitor thc 
prevalence of resistance and guide clinicians in theii- treatment 
choices. 
Resistance in Sfreyitocorcirs pncumuttiae has become a global concern 
in recent years. The Alexander Project reports a high prevalence of 
penicillin resistance in many regions, p.irticularly in Spain, Fraiicc, 
Mexico, the USA and Hong Kong. The trend of resi\tance is up- 
wards, even in regions where resistance has been low, h c h  a\ the UK, 
Germany and other northern European countries. The prevalence of 
niacrolide resistance is also increasing dramatically, and h'is reached 
significant levels (2O'h+)  in many areas, and exceptionally high levels 
in South East Asia (almost 8l)% in Hong Kong). The prevalence of 
beta-lactaiiiase-producing strains of Harrmphilus ir!fltrcrrzar has also 
increased significantly in recent years, but may be leveling off in those 
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countries where rates have reached 30-40%. In addition, this patho- 
gen has low intrinsic susceptibility to macrolides. Additionally, the 
vast majority of Moraxella catarrhalis strains now produce beta- 
lactamase-90-100% in many regions-making many beta-lactams 
of limited value in empirical treatment of infections that may be 
caused by H .  iq'henzae or M .  catarrhalis. 
These findings emphasize the need for the use of effective 
antibiotics to overcome the problem of resistance, the continued 
epidemiologic monitoring of antimicrobial resistance, both globally 
and locally, and the importance of reassessing current antimicrobial 
practice. 
F l  Predicting clinical success in community 
respiratory tract infections 
F. Goldstein. Laboratoire de Microbiologie Medicale Fundation, Paris, 
France 
Increasing antibiotic resistance across many parts of the world means 
that rational and evidence-based choices for antibiotic treatments are 
becoming increasingly important if the consequences of resistance are 
to be minimized. Prescribers may find that they need to reassess their 
current antibiotic choices based on criteria which can predict 
bacteriologic and clinical success. Animal models and clinical studies 
have shown that pharmacokinetic and pharmacodynamic (PD) 
parameters are the key to predicting optimal clinical efficacy. 
For beta-lactams and some macrolides, the time for which the 
serum concentration exceeds the MIC is an accurate determinant of 
efficacy. Bacteriologic success is achieved with a time above MIC of 
40% of the dosage interval for penicillins, and 50% for cephalosporins 
and some macrolides. For azithrornycin and quinolones, AUC/MIC 
ratio is the key PD parameter. An AUC/MIC ratio of 25 is generally 
thought to predict good bacteriologic efficacy for non-serious 
infections in ininiunocompetent patients. The utility of PD para- 
meters for predicting bacteriologic and clinical outcomes has been 
correlated with outcomes in otitis media and sinusitis, and confirmed 
in an otitis media clinical model. Using PD parameters, MIC break- 
points predictive of clinical outcome can be defined. These break- 
points, based on the serum concentration of antibiotic present for a 
given percentage of the dosing interval and used in conjunction with 
MIC data from local surveillance studies, predict the susceptibility of 
clinical isolates to individual antibiotics. Using these criteria, 
amoxycillin/clavulanate is identified as the antibiotic of choice for 
empirical treatment of respiratory tract infections, with the exception 
of infections due to atypical microorganisms. 
ml SB-265805 (SB), a potent new quinolone 
A.R. MacGowan. BCARE, Southmead Hospital, Bristol, UK 
SB (LB 20304a) is a new quinolone which has an oxime-derivatized 
(aminomethyl) pyrrolidine substituent at C7 conferring strong 
Gram-positive and -negative activity plus favorable pharniaco- 
kinetics. MIGo values are low against a range of respiratory patho- 
gens when compared to other quinolones. 
SB MICm are: <=0.06 mg/L for group A streptococci, MSSA, 
E. coli, Enterobacter aerogenes and Salmonella; 0.12-0.25 mg/L for 
Enterobacter cloacae, Klebsiella spp. and Proteus vulgaris; /=0.5 mg/L for 
Proteus mirabilis, Morganella morgani, Serratia, Citrobacter, enterococci 
and MRSA. SB is bactericidal against Streptococcus pneumoniae (SP), 
Haemophilus injnenzae (HI), Moraxella cutarrhalis , Staphylococcus aureus, 
E .  coli and Pseudomonas aeruginosa and has a PAE of 2 h with 
Staphylococcus aureus and 19 h with E. coli. Compared to other new 
quinolones such as grepafloxacin, levofloxacin or trovafloxacin, SB is 
more active against quinolone-resistant HI or SP strains. A standard 
20 mg/kg dose in rats resulted in a 1.5-fold greater AUC (IV dose), 
a 2-fold greater C,,, and a similar t 112 to ciprofloxacin. SB is likely 
to have clinically useful activity against pathogens causing RTI, 
including those resistant to present quinolones. 
ml Clinical outcomes in a resistance environment 
U. Schaad. UfLiversiry o/Basel, Department o f  Pediatrics, Basel, 
Switzerland 
Increasing antibiotic resistance has a negative impact on the treatment 
of respiratory tract infection (RTI), but the true extent of this impact 
has remained largely unquantified. Recent studies in acute otitis 
media have established the double tap methodology (tympanocentesis 
on day 1 and day 4-5 of treatment) as an effective clinical model, 
allowing investigation of the link between antibiotic resistance and 
antibiotic efficacy as determined by successful bacterial eradication 
and clinical outcome. Double tap studies show a good correlation 
between increasing MICs and increasing bacteriological failure rates, 
as well as showing correlation between bacteriological activity and 
clinical efficacy. Bacteriological eradication on day 4-5 gives a 97% 
chance of clinical success. Failure to eradicate pathogens results in 
clinical failure in around 40% of patients. Double tap studies also 
show that successful bacteriological eradication is linked to a greater 
improvement in clinical outcome, as shown by reduction of signs and 
symptoms. This clinical model confirms the need to use potent 
antibacterial agents that are able to eradicate the pathogen from the 
site of infection. Beta-lactams such as amoxycillin +clavulanate and 
cefiiroxime currently remain the first choice for acute otitis media 
based on good bacterial eradication of Streptococcus Pneumaniae 
(including intermediate penicillin-resistant strains) and Haemophilus 
inzuenzae (including beta-lactamase-producing strains). 
Infections and cytokines 
m] IL-12 and TNF in infections 
C.A. Dinarello. University of Colorado, Infectious Diseases, Denver, 
co, USA 
The inflammatory cytokines IL-1 and TNF have the same spectrum 
of properties as bacterial products. When administered to humans, 
these cytokines are as toxic as bacterial products. Attention has now 
focused on the concept that the biological properties of IL-1 and 
TNF should be blocked. Blocking IL-1 or TNF has been highly 
successful in patients with rheumatoid arthritis, inflammatory bowel 
disease or graft versus host disease. However, despite a large body of 
animal data, anti-cytokine therapy for sepsis has been disappointing. 
Over 13 000 patients with septic shock have entered trials with TNF- 
neutralizing antibodies, soluble TNF receptors and IL-1 receptor 
antagonist in double-blind, placebo-controlled trials. Although there 
has been a highly consistent small (2-3% increase in 28-day survival 
with anti-cytokine therapy, the effect has not been statistically 
significant. Certain subgroups, such as patients with disseminated 
intravascular coagulation, show remarkable improvement with anti- 
TNF therapy. Meta-analysis of anti-cytokine therapy in sepsis 
concluded that the benefit was small because the sample size of each 
trial is small. Also, no harm appears to be associated with anti- 
cytokine therapy. A combination of blocking TNF and IL-1 may 
offer the patient with Gram-negative septic shock the greatest chance 
of rescue. Another approach is to treat patients with immuno- 
